Pharmacology and clinical use of voriconazole

Bibliography

• Elizabeth SDA, Russel L, James SL, Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43(s1):S28-39
   Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-60
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998;17(8):573-75
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39(3):954-8
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001;150(3):101-15
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008;47(2):226-35
   PubMed Web of Science ®Google Scholar
• Shimokawa O, Nakayama H. Increased sensitivity of Candida albicans cells accumulating 14 alpha-methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents. Antimicrob Agents Chemother 1992;36(8):1626-9
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36(5):630-7
   PubMed Web of Science ®Google Scholar
• Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001;21(8 Pt2):133S-48S
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45(6):1735-45
   PubMed Web of Science ®Google Scholar
• Panackal AA, Gribskov JL, Staab JF, Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006;44(5):1740-3
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008;46(2):515-21
   PubMed Web of Science ®Google Scholar
• Fukuoka T, Johnston DA, Winslow CA, Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother 2003;47(4):1213-19
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Fiori B, Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005;49(2):668-79
   PubMed Web of Science ®Google Scholar
• EUCAST clinical breakpoints. Available from: http://www.srga.org/eucastwt/MICTAB/index.html. [Accessed 1 Nov 2009]
   Google Scholar
• Pfaller MA, Diekema DJ, Rex JH, Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006;44:819-26
   PubMed Web of Science ®Google Scholar
• Slaven JW, Anderson MJ, Sanglard D, Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol 2002;36(3):199-206
   PubMed Web of Science ®Google Scholar
• Mann PA, Parmegiani RM, Wei SQ, Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother 2003;47(2):577-81
   PubMed Web of Science ®Google Scholar
• Mellado E, Garcia-Effron G, Alcazar-Fuoli L. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004;48(7):2747-50
   PubMed Web of Science ®Google Scholar
• Howard SJ, Cerar D, Anderson MJ, Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15(7):1068-76
   PubMed Web of Science ®Google Scholar
• Mellado E, Garcia-Effron G, Alcazar-Fuoli L, A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007;51(6):1897-904
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008;46(8):2568-72
   PubMed Web of Science ®Google Scholar
• Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007;356(14):1481-3
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46(8):2546-53
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Kleinermans D, Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003;56(Suppl 1):17-23
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Blumer JL, Yanovich S, Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002;42(4):395-402
   PubMed Web of Science ®Google Scholar
• Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37(5):728-32
   PubMed Web of Science ®Google Scholar
• Voriconazole (Vfend) Summary of Product Characteristics. Available at: http://emc.medicines.org.uk/document.aspx?documentId=10059 [last accessed September 2009]
   Google Scholar
• Weiler S, Zoller H, Graziadei I, Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis. Antimicrob Agents Chemother 2007;51(9):3459-60
   PubMed Web of Science ®Google Scholar
• Groll AH, Gea-Banacloche JC, Glasmacher A, Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003;17(1):159-91, ix
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45(7):649-63
   PubMed Web of Science ®Google Scholar
• Pfizer Global Research and Development. Briefing Document for Voriconazole ftFADPAC, 1-56, 2001. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf. [Last accessed 3 July 2009]
   Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T, Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004;48(6):2166-72
   PubMed Web of Science ®Google Scholar
• Mikus G, Schowel V, Drzewinska M, Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80(2):126-35
   PubMed Web of Science ®Google Scholar
• Bruggemann RJ, Alffenaar JW, Blijlevens NM, Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48(10):1441-58
   PubMed Web of Science ®Google Scholar
• Moriyama B, Elinoff J, Danner RL, Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother 2009;53(4):1712-14
   PubMed Web of Science ®Google Scholar
• Mulanovich V, Lewis RE, Raad II, Kontoyiannis DP. Random plasma concentrations of voriconazole decline over time. J Infect 2007;55(5):e129-30
   PubMedGoogle Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:24-34
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):563-71
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V, Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50(4):1570-2
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46(2):201-11
   PubMed Web of Science ®Google Scholar
• Trifilio S, Ortiz R, Pennick G, Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35(5):509-13
   PubMed Web of Science ®Google Scholar
• Ally R, Schurmann D, Kreisel W, A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33(9):1447-54
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346(4):225-34
   PubMed Web of Science ®Google Scholar
• Scherpbier HJ, Hilhorst MI, Kuijpers TW. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis 2003;37(6):828-30
   PubMed Web of Science ®Google Scholar
• Philips JA, Marty FM, Stone RM, Torsades de pointes associated with voriconazole use. Transpl Infect Dis 2007;9(1):33-6
   PubMed Web of Science ®Google Scholar
• Lewis RE. What is the “therapeutic range” for voriconazole? Clin Infect Dis 2008;46(2):212-14
   PubMed Web of Science ®Google Scholar
• Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis 2008;47(1):e7-10
   PubMed Web of Science ®Google Scholar
• Pai MP, Allen S. Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis 2003;36(8):1089-91
   PubMed Web of Science ®Google Scholar
• Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71(4):226-34
   PubMed Web of Science ®Google Scholar
• Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55(5):481-5
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56(Suppl 1):37-44
   PubMed Web of Science ®Google Scholar
• Liu P, Foster G, Gandelman K, Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51(10):3617-26
   PubMed Web of Science ®Google Scholar
• Liu P, Foster G, LaBadie RR, Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008;48(1):73-84
   PubMed Web of Science ®Google Scholar
• Liu P, Foster G, Labadie R, Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother 2007;51(1):110-18
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;56(Suppl 1):24-9
   PubMed Web of Science ®Google Scholar
• Gerzenshtein L, Patel SM, Scarsi KK, Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother 2005;39(7-8):1342-5
   PubMed Web of Science ®Google Scholar
• Geist MJ, Egerer G, Burhenne J, Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother 2007;51(9):3455-6
   PubMed Web of Science ®Google Scholar
• Voriconazole package insert. Available from: http://www.pfizer.com/files/products/uspi_vfend.pdf. [Accessed 1 Nov 2009]
   Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366(9495):1435-42
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36(9):1122-31
   PubMed Web of Science ®Google Scholar
• Thompson GR III, Wiederhold NP, Sutton DA, In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 2009;64(1):79-83
   PubMed Web of Science ®Google Scholar
• Fournier S, Pavageau W, Feuillhade M, Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2002;21(12):892-6
   PubMed Web of Science ®Google Scholar
• Girmenia C, Pagano L, Martino B, Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005;43(4):1818-28
   PubMed Web of Science ®Google Scholar
• Asada N, Uryu H, Koseki M, Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006;43(4):e39-41
   PubMed Web of Science ®Google Scholar
• Bouza E, Munoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 2004;10(Suppl 1):76-85
   PubMed Web of Science ®Google Scholar
• Riedel DJ, Johnson JK, Forrest GN. Rhodotorula glutinis fungemia in a liver-kidney transplant patient. Transpl Infect Dis 2008;10(3):197-200
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36(1):198-202
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Petroelje B, Messer SA, Activities of available and investigational antifungal agents against rhodotorula species. J Clin Microbiol 2005;43(1):476-8
   PubMed Web of Science ®Google Scholar
• da Matta VL, de Souza Carvalho Melhem M, Colombo AL, Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. Antimicrob Agents Chemother 2007;51(4):1573-6
   PubMed Web of Science ®Google Scholar
• Garau M, Pereiro M Jr, del Palacio A. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob Agents Chemother 2003;47(7):2342-4
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45(7):807-25
   PubMed Web of Science ®Google Scholar
• Chapman SW, Bradsher RW Jr, Campbell GD Jr, Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):679-83
   PubMed Web of Science ®Google Scholar
• Galgiani JN, Ampel NM, Catanzaro A, Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):658-61
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):684-7
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001;7(Suppl 2):8-24
   PubMed Web of Science ®Google Scholar
• Gonzalez GM, Fothergill AW, Sutton DA, In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005;43(3):281-4
   PubMed Web of Science ®Google Scholar
• Li RK, Ciblak MA, Nordoff N, In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000;44(6):1734-6
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Nordoff N, Li RK, Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med Mycol 2001;39(4):369-71
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46(4):1032-7
   PubMed Web of Science ®Google Scholar
• Freifeld A, Proia L, Andes D, Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009;53(4):1648-51
   PubMed Web of Science ®Google Scholar
• Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg 2007;77(2):350-3
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Goldani LZ, Schlamm HT, An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007;45(11):1462-9
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15
   PubMed Web of Science ®Google Scholar
• Schwartz S, Ruhnke M, Ribaud P, Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005;106(8):2641-5
   PubMed Web of Science ®Google Scholar
• Mouas H, Lutsar I, Dupont B, Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005;40(8):1141-7
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G, Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006;81(3):320-6
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39(6):797-802
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, Results of fluconazole (FLU) vs voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients [abstract #163]. Blood 2007;110:55a
   Web of Science ®Google Scholar
• Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE, Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60
   PubMed Web of Science ®Google Scholar
• Lamaris GA, Ben-Ami R, Lewis RE, Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009;199:1399-406
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21(3):240-8
   PubMed Web of Science ®Google Scholar
• Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004;137(5):820-5
   PubMed Web of Science ®Google Scholar
• O'Day DM, Head WS, Robinson RD, Intraocular penetration of systemically administered antifungal agents. Curr Eye Res 1985;4(2):131-4
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WF, Holz ER, Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;92(7):42-7
   Google Scholar
• Vemulakonda GA, Hariprasad SM, Mieler WF, Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008;126(1):18-22
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WF, Lin TK, Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008;92(7):871-8
   PubMed Web of Science ®Google Scholar
• Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrob Agents Chemother 2009;53(2):798-9
   PubMed Web of Science ®Google Scholar
• Azoles (Clotrimazole F, Itraconazole, Ketoconazole, Miconazole, Voriconazole, Posaconazole). In: Antimicrobial Therapy and Vaccines. Available at: http://www.antimicrobe.org. [Accessed September 2008]
   Google Scholar